Sign in

    Patrick J. Beyer

    President and Chief Executive Officer (CEO) at Conmed Corp
    Board
    Since January 1, 2025
    Age
    59 years
    Education
    Holds a Bachelor of Arts in Economics from Kalamazoo College, an MBA in Finance from Western Michigan University, and completed the Advanced Management Program at Harvard Business School.
    Tenure
    Joined CNMD in December 2014 as President of CONMED International, later promoted to oversee International and Global Orthopedics in October 2020, advanced to COO in April 2024, and assumed the role of President and CEO effective January 1, 2025.

    Also at Conmed Corp

    BL
    Brent Lalomia
    Vice President, Quality Assurance, Regulatory Affairs, Customer Experience, and Logistics
    EC
    Edward Clifford
    Vice President, Global Manufacturing
    JF
    John Ferrell
    Executive Vice President, Human Resources

    About

    The executive is 59 years old and holds a strong educational background with a Bachelor of Arts in Economics from Kalamazoo College, an MBA in Finance from Western Michigan University, and completion of the Advanced Management Program at Harvard Business School.

    Beginning his career at CNMD in December 2014 as President of CONMED International, he advanced through multiple leadership roles. His tenure included a promotion to oversee International and Global Orthopedics in October 2020, followed by an appointment as Chief Operating Officer in April 2024, culminating in his current role as President and Chief Executive Officer effective January 1, 2025.

    Before joining CNMD, he accumulated extensive experience in the healthcare industry, including a 21-year leadership tenure at Stryker Corporation and serving as CEO at ICNet. His background is further enhanced by his board memberships, notably with Bioventus, underscoring a robust career in strategic and operational roles within the medical sector.

    $CNMD Performance Under Patrick J. Beyer

    Past Roles

    OrganizationRoleDate RangeDetails
    CNMDChief Operating Officer (COO)Starting April 2024Held role before becoming President and CEO
    CNMDPresident, International and Global OrthopedicsOctober 2020 to April 2024Included additional responsibility for the U.S. Orthopedics business
    CNMDPresident of CONMED InternationalDecember 2014 to October 2020Served in this role prior to further leadership transitions
    ICNetChief Executive Officer (CEO)2010 to 2014Privately held infectious control software company; sold in 2014
    Stryker CorporationLed Stryker Europe2005 to 2009Leadership role in Europe
    Stryker CorporationLed Stryker UK, South Africa, and Ireland2002 to 2005Leadership role covering multiple regions
    Stryker CorporationLed Stryker Medical1999 to 2002Leadership role in the medical division

    External Roles

    OrganizationRoleDate RangeDetails
    BioventusBoard Member (Audit Committee)N/AMember of Audit Committee
    AxenicBoard MemberN/AN/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmount (USD)Payment ScheduleAdditional Details
    Base Salary$548,926 AnnualPaid in British pounds; converted to U.S. dollars using an exchange rate of £0.7868 to $1.00
    401(k) Employer Contributions$0 N/ANot provided; Mr. Beyer participates in a UK program instead of a U.S.-based 401(k)
    Benefits Restoration Plan$0 N/ADoes not receive contributions under the Benefits Restoration Plan
    Other Fixed Payments$545,070 AnnualIncludes retirement plan payments, car allowance, car repairs, personal air travel costs, and more

    Performance Compensation

    Data from  FY 2023

    Non-Equity Incentive Compensation (Executive Bonus)

    Performance MetricThreshold (%)Target (%)Maximum (%)Actual Performance (% of Target)
    Net Sales (FX Adjusted)4.80 24.00 48.00 109.7
    Adjusted Diluted Net EPS6.40 32.00 64.00 150.0
    Free Cash Flow0.80 4.00 8.00 135.0
    Commercial Goals4.00 20.00 40.00 59.4
    Overall Bonus16.00 80.00 160.00 114.5
    • Bonus Target: 80% of base salary
    • Actual Bonus Payout: 91.6% of base salary, amounting to $505,300

    Equity Awards

    Stock Options

    ComponentGrant DateNumber of OptionsExercise Price (USD)Vesting ScheduleExpiration DateAdditional Details
    Stock OptionsMarch 1, 2023 32,212 $96.16 20% vesting annually over 5 years March 1, 2033 Grant date fair value of $1,274,951

    Performance Stock Units (PSUs)

    ComponentGrant DateTarget UnitsVesting SchedulePerformance MetricsPayout RangeAdditional Details
    PSUsMarch 1, 2023 2,920 Cliff vest after 3-year performance period Relative TSR vs. S&P Healthcare Equipment Select IndexThreshold (25th percentile): 50% payout; Target (50th percentile): 100% payout; Maximum (75th percentile+): 200% payout Grant date fair value of $425,064

    Evaluation Period: 2023 for the non-equity bonus with performance measured against preset financial metrics.

    Note: The stock options are time-based awards, whereas the PSUs incorporate performance thresholds tied to the company’s relative Total Shareholder Return (TSR) compared to its industry benchmark.